Company intelligence / Profile preview

PK-137

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

PK-137 was a biotechnology company focused on the development of small molecule inhibitors for the treatment of Parkinson's disease. The company specifically targeted Leucine-rich repeat kinase 2 (LRRK2), a protein whose mutations are a common genetic cause of the disease. PK-137's research aimed to identify potent and selective inhibitors that could cross the blood-brain barrier to slow or stop disease progression. The company was eventually acquired by Centogene to integrate its drug discovery assets into a broader precision medicine platform.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on PK-137.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PK-137.

Explore the full profile